BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16960923)

  • 1. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis.
    Kavanaugh A; Antoni C; Mease P; Gladman D; Yan S; Bala M; Zhou B; Dooley LT; Beutler A; Guzzo C; Krueger GG
    J Rheumatol; 2006 Nov; 33(11):2254-9. PubMed ID: 16960923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    van der Heijde D; Han C; DeVlam K; Burmester G; van den Bosch F; Williamson P; Bala M; Han J; Braun J
    Arthritis Rheum; 2006 Aug; 55(4):569-74. PubMed ID: 16874778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
    Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
    Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
    Kavanaugh A; Krueger GG; Beutler A; Guzzo C; Zhou B; Dooley LT; Mease PJ; Gladman DD; de Vlam K; Geusens PP; Birbara C; Halter DG; Antoni C;
    Ann Rheum Dis; 2007 Apr; 66(4):498-505. PubMed ID: 17114188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
    Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
    Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab treatment maintains employability in patients with early rheumatoid arthritis.
    Smolen JS; Han C; van der Heijde D; Emery P; Bathon JM; Keystone E; Kalden JR; Schiff M; Bala M; Baker D; Han J; Maini RN; St Clair EW
    Arthritis Rheum; 2006 Mar; 54(3):716-22. PubMed ID: 16508932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
    Kavanaugh A; Antoni C; Krueger GG; Yan S; Bala M; Dooley LT; Beutler A; Guzzo C; Gladman D
    Ann Rheum Dis; 2006 Apr; 65(4):471-7. PubMed ID: 16096330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of infliximab in resistant psoriatic arthritis.
    Salvarani C; Cantini F; Olivieri I; Macchioni P; Padula A; Niccoli L; Catanoso MG; Scocco GL; Boiardi L
    Arthritis Rheum; 2003 Aug; 49(4):541-5. PubMed ID: 12910561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
    van der Heijde D; Kavanaugh A; Gladman DD; Antoni C; Krueger GG; Guzzo C; Zhou B; Dooley LT; de Vlam K; Geusens P; Birbara C; Halter D; Beutler A
    Arthritis Rheum; 2007 Aug; 56(8):2698-707. PubMed ID: 17665424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.
    Braun J; Landewé R; Hermann KG; Han J; Yan S; Williamson P; van der Heijde D;
    Arthritis Rheum; 2006 May; 54(5):1646-52. PubMed ID: 16646033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
    Kivitz AJ; Espinoza LR; Sherrer YR; Liu-Dumaw M; West CR
    Semin Arthritis Rheum; 2007 Dec; 37(3):164-73. PubMed ID: 17570469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
    Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
    Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
    Ruperto N; Lovell DJ; Cuttica R; Wilkinson N; Woo P; Espada G; Wouters C; Silverman ED; Balogh Z; Henrickson M; Apaz MT; Baildam E; Fasth A; Gerloni V; Lahdenne P; Prieur AM; Ravelli A; Saurenmann RK; Gamir ML; Wulffraat N; Marodi L; Petty RE; Joos R; Zulian F; McCurdy D; Myones BL; Nagy K; Reuman P; Szer I; Travers S; Beutler A; Keenan G; Clark J; Visvanathan S; Fasanmade A; Raychaudhuri A; Mendelsohn A; Martini A; Giannini EH; ;
    Arthritis Rheum; 2007 Sep; 56(9):3096-106. PubMed ID: 17763439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study.
    Kapp A; Pichler WJ
    Int J Dermatol; 2006 Apr; 45(4):469-74. PubMed ID: 16650180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.